175 related articles for article (PubMed ID: 15197484)
1. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD
Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484
[TBL] [Abstract][Full Text] [Related]
2. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
3. The role of minocycline in the treatment of intracranial 9L glioma.
Weingart JD; Sipos EP; Brem H
J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model.
Weingart JD; Thompson RC; Tyler B; Colvin OM; Brem H
Int J Cancer; 1995 Sep; 62(5):605-9. PubMed ID: 7665233
[TBL] [Abstract][Full Text] [Related]
5. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy.
Storm PB; Moriarity JL; Tyler B; Burger PC; Brem H; Weingart J
J Neurooncol; 2002 Feb; 56(3):209-17. PubMed ID: 12061726
[TBL] [Abstract][Full Text] [Related]
6. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H
Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184
[TBL] [Abstract][Full Text] [Related]
7. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
8. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
Frazier JL; Wang PP; Case D; Tyler BM; Pradilla G; Weingart JD; Brem H
J Neurooncol; 2003 Sep; 64(3):203-9. PubMed ID: 14558595
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T
Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626
[TBL] [Abstract][Full Text] [Related]
10. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Bow H; Hwang LS; Schildhaus N; Xing J; Murray L; Salditch Q; Ye X; Zhang Y; Weingart J; Brem H; Tyler B
J Neurosurg; 2014 Mar; 120(3):662-9. PubMed ID: 24359008
[TBL] [Abstract][Full Text] [Related]
11. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Tamargo RJ; Myseros JS; Epstein JI; Yang MB; Chasin M; Brem H
Cancer Res; 1993 Jan; 53(2):329-33. PubMed ID: 8417826
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Sampath P; Amundson E; Wall ME; Tyler BM; Wani MC; Alderson LM; Colvin M; Brem H; Weingart JD
J Neurosurg; 2003 Mar; 98(3):570-7. PubMed ID: 12650430
[TBL] [Abstract][Full Text] [Related]
13. Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Saito R; Bringas J; Mirek H; Berger MS; Bankiewicz KS
J Neurosurg; 2004 Nov; 101(5):826-31. PubMed ID: 15540922
[TBL] [Abstract][Full Text] [Related]
14. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
[TBL] [Abstract][Full Text] [Related]
15. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.
Khil MS; Kolozsvary A; Apple M; Kim JH
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):511-6. PubMed ID: 10802380
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma.
Lee JS; An TK; Chae GS; Jeong JK; Cho SH; Lee HB; Khang G
Eur J Pharm Biopharm; 2005 Jan; 59(1):169-75. PubMed ID: 15567315
[TBL] [Abstract][Full Text] [Related]
17. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.
Kim GY; Tyler BM; Tupper MM; Karp JM; Langer RS; Brem H; Cima MJ
J Control Release; 2007 Nov; 123(2):172-8. PubMed ID: 17884232
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
[TBL] [Abstract][Full Text] [Related]
19. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Zhang RX; Dougherty DV; Rosenblum ML
Chin Med J (Engl); 1990 Aug; 103(8):658-65. PubMed ID: 2122945
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat.
Lillehei KO; Kong Q; Withrow SJ; Kleinschmidt-DeMasters B
Neurosurgery; 1996 Dec; 39(6):1191-7; discussion 1197-9. PubMed ID: 8938774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
